Neuroinflamação na Doença de Alzheimer: mecanismos patológicos e potenciais alvos terapêuticos
DOI:
https://doi.org/10.34119/bjhrv6n4-123Keywords:
Doença de Alzheimer, neuroinflamação, mecanismos patológicos, alvos terapêuticos, modulação da neuroinflamaçãoAbstract
A doença de Alzheimer (DA), uma condição neurodegenerativa progressiva, está associada à neuroinflamação crônica, que desempenha um papel fundamental em sua patogênese. Neste artigo de revisão, examinamos os mecanismos patológicos da neuroinflamação na DA e exploramos os potenciais alvos terapêuticos identificados na literatura recente. As células da glia, especialmente a microglia e os astrócitos, são cruciais para a mediação da neuroinflamação na DA. Estratégias terapêuticas que buscam modulação da neuroinflamação, incluindo a imunoterapia, modulação de microglia e astrócitos, e inibidores de citocinas pró-inflamatórias, mostram grande potencial. No entanto, o desenvolvimento de tratamentos eficazes enfrenta desafios, incluindo a identificação precisa de alvos terapêuticos e a administração de medicamentos no cérebro. A compreensão dos mecanismos precisos da neuroinflamação na DA é fundamental para o avanço da pesquisa e do tratamento desta doença devastadora.References
BARROS. Everton Philipe da Silva. A Utilização de Ressonância Magnética no auxílio do Diagnóstico da Doença de Alzheimer. Monografia apresentada ao Curso de Especialização em Imagenologia Biomédica (CCE), como requisito para obtenção do grau de Especialista em Imagenologia Biomédica. Instituto Nacional de Ensino Sociedade e Pesquisa – INESP.Centro de Capacitação Educacional,2017.
BEN HAIM, L. et al. The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases. Journal of Neuroscience, v. 35, n. 6, p. 2817-2829, 2015.
CHAKRABARTY, P. et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron, v. 85, n. 3, p. 519-533, 2015.
COLLINS, J. M. et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Experimental Neurology, v. 315, p. 18-24, 2019.
CUMMINGS, J. et al. Alzheimer's disease drug development pipeline: 2019. Alzheimer's & Dementia: Translational Research & Clinical Interventions, v. 5, p. 272-293, 2019.
FARLOW, M. et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimer's Research & Therapy, v. 4, n. 3, p. 23, 2012.
GRIFFIN, W. S. T. et al. Interleukin-1 mediates Alzheimer and Lewy body pathologies. Journal of Neuroinflammation, v. 3, n. 1, p. 5, 2006.
HENSTRIDGE, C. et al. The role of neuroinflammation in dementias. Current Alzheimer Research, v. 16, n. 4, p. 295-317, 2019.
HONIG, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer's disease. New England Journal of Medicine, v. 378, n. 4, p. 321-330, 2018.
ILLES, P. et al. P2Y1 receptors as a new target for cognitive impairments in neurological diseases. Molecular Psychiatry, v. 25, n. 2, p. 329-340, 2020.
KUMAR, A. et al. Neuroinflammation in Alzheimer's disease: The preventive and therapeutic potential of polyphenolic nutraceuticals. Advances in Protein Chemistry and Structural Biology, v. 118, p. 235-265, 2020.
LANE, C. A.; HARDY, J.; SCHOTT, J. M. Alzheimer's disease. European Journal of Neurology, v. 25, n. 1, p. 59-70, 2018.
LEE, J. K. et al. Therapeutic modulation and reestablishment of the intestinal microbiota with fecal microbiota transplantation resolves sepsis and diarrhea in a patient. American Journal of Gastroenterology, v. 109, n. 11, p. 1832-1834, 2020.
LEE, S. J. et al. MicroRNA-124-loaded nanoparticles increase survival and neuronal differentiation of neural stem cells in vitro but do not contribute to stroke outcome in vivo. PloS One, v. 13, n. 4, e0193609, 2018.
LONG, J. M.; HOLTZMAN, D. M. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, v. 179, n. 2, p. 312-339, 2019.
McGEER, P. L. et al. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiology of Aging, v. 28, n. 5, p. 639-647, 2006.
OLMOS-ALONSO, A. et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. Brain, v. 139, n. 3, p. 891-907, 2016.
ORGOGOZO, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology, v. 61, n. 1, p. 46-54, 2003.
OSTROWITZKI, S. et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Archives of Neurology, v. 69, n. 2, p. 198-207, 2017.
PEIXOTO. Clarice Teixeira da Silva. Saúde Mental: Um Enfoque Voltado á Prevenção da Demência de Alzheimer.International Journal of Health Management – v. 7, n. 3, 2021.
SCIMEMI, A. et al. Amyloid-β1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. Journal of Neuroscience, v. 33, n. 12, p. 5312-5318, 2013.
SASTRE, M. et al. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. International Journal of Developmental Neuroscience, v. 24, n. 2-3, p. 167-176, 2006.
SEVIGNY, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, v. 537, n. 7618, p. 50-56, 2016.
SHI, J. Q. et al. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Research, v. 1368, p. 239-247, 2011.
SOFRONIEW, M. V. Astrocyte barriers to neurotoxic inflammation. Nature Reviews Neuroscience, v. 16, n. 5, p. 249-263, 2015.
TOBINICK, E. L. et al. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurology, v. 8, p. 27, 2008.
TOBINICK, E. et al. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed, v. 8, n. 2, p. 25, 2006.
VLAD, S. C. et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology, v. 70, n. 19, p. 1672-1677, 2008.
WINBLAD, B. et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. The Lancet Neurology, v. 11, n. 7, p. 597-604, 2012.
WORLD HEALTH ORGANIZATION. Dementia. 2021. Disponível em: https://www.who.int/news-room/fact-sheets/detail/dementia. Acesso em: 15 jun. 2023.
